About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- Human, healthy adults aged 21-61
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Single-dose design (not chronic/repeated dosing); the only human clinical study of CJC-1295 identified.
Cited in
Growth hormone and IGF-1 elevation
CJC-1295 · Research finding
Limited
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.